Hillman Solutions is rated a 'buy' for rising profitability, strong cash flow, and undervalued shares. Click here to read the latest analysis of HLMN stock.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...
Discover the implications of the proposed NXP, NXC & NXN merger on yields and taxes for muni bond investors. Click to see how this impacts your portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback